FunctionTranscriptional activator required for lipid homeostasis. Regulates transcription of the LDL receptor gene as well as the cholesterol and to a lesser degree the fatty acid synthesis pathway (By similarity). Binds the sterol regulatory element 1 (SRE-1) (5'-ATCACCCCAC-3') found in the flanking region of the LDRL and HMG-CoA synthase genes.
Tissue specificityUbiquitously expressed in adult and fetal tissues.
Sequence similaritiesBelongs to the SREBP family. Contains 1 basic helix-loop-helix (bHLH) domain.
Post-translational modificationsAt low cholesterol the SCAP/SREBP complex is recruited into COPII vesicles for export from the ER. In the Golgi complex SREBPs are cleaved sequentially by site-1 and site-2 protease. The first cleavage by site-1 protease occurs within the luminal loop, the second cleavage by site-2 protease occurs within the first transmembrane domain and releases the transcription factor from the Golgi membrane. Apoptosis triggers cleavage by the cysteine proteases caspase-3 and caspase-7.
Cellular localizationNucleus and Endoplasmic reticulum membrane. Golgi apparatus membrane. Cytoplasmic vesicle > COPII-coated vesicle membrane. Moves from the endoplasmic reticulum to the Golgi in the absence of sterols.
All lanes : Anti-SREBP2 antibody (ab112046) at 0.4 µg/ml
Lane 1 : HeLa whole cell lysate at 50 µg Lane 2 : HeLa whole cell lysate at 15 µg Lane 3 : HeLa whole cell lysate at 5 µg Lane 4 : 293T whole cell lysate at 50 µg
developed using the ECL technique
Predicted band size : 124 kDa
Exposure time : 3 minutes
Immunoprecipitation - SREBP2 antibody (ab112046)
Detection of SREBP2 by Western Blot of Immunprecipitate.
Lane 1: ab112046 at 1µg/ml staining SREBP2 in HeLa whole cell lysate immunoprecipitated using ab112046 at 6µg/mg lysate (1 mg/IP; 20% of IP loaded/lane). Lane 2: Control IgG
Detection: Chemiluminescence with exposure time of 30 seconds.
References for Anti-SREBP2 antibody (ab112046)
This product has been referenced in:
Li X et al. Fatostatin displays high antitumor activity in prostate cancer by blocking SREBP-regulated metabolic pathways and androgen receptor signaling. Mol Cancer Ther13:855-66 (2014).
Read more (PubMed: 24493696) »